Arena Pharmaceuticals, Inc.

China’s retaliatory tariffs mean the option of manufacturing US-originated drugs in China is making more sense than ever, at least to some local partners of US pharmaceutical companies. China imposed

After pulling back on M&A last year to digest the $43bn acquisition of Seagen in 2023, Pfizer said it is in a position to complete bigger deals this year, but that the company will be strategic ab

In the top alliance by deal value, Monte Rosa Therapeutics granted Novartis exclusive global rights to develop, manufacture and commercialize Phase I MRT-6160 for immune-mediated conditions as well as

Pfizer, Inc. CEO Albert Bourla went public for the first time during the company’s third quarter sales and earnings call with his view of activist investor Starboard Value buying a $1bn stake in the c